The recent publication of negative results in the second large double-blind controlled trial of hyperbaric oxygenation in multiple sclerosis (MS) undertaken in Britain', confirming those reported in the early part of 1985 from the Newcastle group2, would appear to refute once and for all the suggestion that hyperbaric oxygen has any role to play in the management of patients with MS. Yet, once again, the results have been criticized in the lay press by members ofthe medical profession, and it would seem inevitable that further correspondence in the medical literature will follow. What then are the facts, and whydespite the initial negative reporthave voluntary organizations since spent thousands of pounds on providing this suggested therapy and the Scottish Home and Health Department provided further substantial funding for a third trial? clinical features of multiple sclerosis and those neurological symptoms described in divers suffering from 'the bends'. He drew attention to the recognized perivenular site ofthe MS plaques and suggested that MS might be due to transient venous occlusion by fat emboli. This hypothesis was criticized severely by neuropathologists, who pointed out that the 'demyelination' seen adjacent to fat emboli is a form of Wallerian degeneration with axonal damage and does not resemble the primary demyelination of MS.
Thus by the end of 1982 there were several uncontrolled clinical reports of benefit to MS patients from hyperbaric oxygenation and two potential theories to explain an effectthe one dependent upon an immunological effect of hyperbaric oxygenation and the other on a specific benefit to ischaemic areas of perivenous cerebral tissue resulting from hyperoxygenation of the blood.
Search for a cure The fact that MS is a disease without proven cause and without establised treatment has led to it being the subject of numerous and often unsubstantiated claims for therapy. During the past three decades patients have been subjected to treatment with oral arsenic, intrathecal injections of tuberculin, oral seaweed, intramuscular rabies vaccine, gluten-free diets, oil ofevening primrose and snake venom. None of these therapies has stood the test of time and most have provided benefit for those involved in supplying the agents rather than for the patients themselves.
The most recent unproven therapy to be suggested is that of hyperbaric oxygenation. The original report linking MS with hyperbaric oxygenation appeared in 1970 from Czechoslovakia3 when it was reported that 15 of 26 patients given oxygen at 2 atmospheres of pressure showed improvement in their clinical state. During the 1970s and into the early 1980s the only reports of hyperbaric oxygenation in MS consisted of uncontrolled case reports of patients, predominantly in the United States of America, who appeared to derive benefit from treatment with 100% oxygen at 2 atmospheres ofpressure. The rationale for hyperbaric oxygen treatment in MS received support from evidence that experimental allergic encephalomyelitis in guinea pigs could be ameliorated by hyperbaric oxygen therapy given before and during immunization4. It was suggested, therefore, that hyperbaric oxygenation might have an effect upon the immune phenomena responsible for experimental allergic encephalomyelitis and by analogy improve the outcome in MS.
In 1982 there appeared in the hypothesis section of the Lancet a paper' which suggested an alternative explanation for the effect of hyperbaric oxygenation in MS. The author drew an analogy between the
Controlled clinical trials
Early in 1983 the report in the New England Journal of Medicine by Fischer et al.6 generated considerable interest in the potential of hyperbaric oxygen therapy. This study consisted of a double-blind controlled trial in 40 patients, 20 of whom were treated with 100% oxygen at 2 atmospheres for 90 minutes during twenty sessions over four weeks, the other 20 being given 10% oxygen at 2 atmospheres of pressure in identical conditions. Three patients in the treatment group failed to complete the protocol, but 12 ofthe remaining 17 showed an improvement in Kurtzke disability status scale compared with only one of the 20 in the control group. At the end of one year, 5 patients in the treated group remained improved compared with one in the control group, and significantly fewer patients had deterioratedonly 2 in the treatment group compared with 11 controls.
Several aspects of this original study gave cause for concern: 12 ofthe patients, who were described as being in a chronic state, showed an improvement in overall performance on the Kurtzke disability status scale within one month, a degree of improvement which is surprising to those accustomed to using this system ofassessment; the 3 patients who were lost for logistical reasons in the treatment group were excluded from all assessments; and the rate of deterioration in the control group of chronic patients after one year was greater than expected. It seems possible that the control therapy providing 20% oxygen but also 180% nitrogenmighthavebeen deleterious to the patients. The authors of this original article pointed out that their study was small, could be regarded asno more than a pilot study and that further assessments were required. Fischer suggested a third possible 0141-0768/86/ 090535-03/$02.00/0 01986 The Royal Society of Medicine reason for the benefit of hyperbaric oxygenation, namely that this treatment might produce a rise in endogenous steroids in the patients and a consequent improvement in their disease.
Later in 1983 James7 reiterated his evidence for fat emboli as a cause of the plaques in MS and showed magnetic resonance imaging pictures of an MS lesion apparently changing after hyperbaric oxygen therapy. The validity of these scans and their interpretation was, however, strongly criticized in the following edition of the same journal by the radiological colleague who had undertaken the investigations.
Such was the position in 1983 when the MS Society of Great Britain and Northern Ireland supported two double-blind controlled trials of hyperbaric oxygenation in patients with chronic MS in Newcastle upon Tyne and London. The first trial was completed in Newcastle in October of 1984 and initial results reported in the Lancet in January 19852. The treated group of patients were given 100% oxygen by facemask in a multiplace chamber at 2 atmospheres of pressure in a regimen identical to that documented by Fischer et al.6 . The control groupwere given air at normal pressure by face-mask whilst sitting in an unpressurized chamber. This trial found no objective benefit from hyperbaric oxygen treatment at the end of the period of therapy. No patient had improved on the Kurtzke disability status scale by the end of the treatment period and one patient in each group had deteriorated by one grade on the scale. There was no significant difference between the two groups in respect of the individual parameters assessed in the Kurtzke scoring system, including pyramidal function, cerebellar function, brainstem function, visual acuity, sensory function or mental state. There was a small but significant subjective improvement in bladder function, but formal urodynamic analysis failed to confirm this apparent benefit in patients receiving hyperbaric oxygen treatment.
Further results are now available from the Newcastle trial after a one year follow-up from the time of treatment and, in addition to continued clinical assessment, patients have been subjected to formal psychological testing, evoked potential studies, T-cell subset studies in peripheral blood and formal urodynamics. There is no evidence that either the clinical condition or the laboratory-based studies reveal any significant benefit for patients treated with hyperbaric oxygen (in preparation).
The results of the London trial, including 42 patients treated and 42 control patients, have now been reported'. This trial was performed in monoplace chambers and the protocol followed was essentially similar to that used in Newcastle in that the treatment group were provided with 100% oxygen at 2 atmospheres of pressure, the control group being given air at 1.1 atmospheres of pressure. Once again, no significant difference was found between objective assessments in either of the groups.
These two trials comprise a total of 204 patients studied under double-blind conditions, and are in agreement with three smaller trials from America8'-0 totalling 115 patients and a further study of 24 patients from Sweden". There are now, therefore, reports on 343 patients treated under control conditions in different parts of the world in whom no significant benefit has been found for the use of hyperbaric oxygen treatment.
Methodological criticisms
Since the first negative trials were reported, there have been several criticisms mounted by the proponents ofthis form oftherapy. The suggestion has been made that a fixed pressure of 2 atmospheres at which to deliver oxygen is not the ideal treatment and that the level of pressure used needs to be carefully titrated to the needs and condition of the patient. This is, of course, an unanswerable criticism, but it remains true that the initial uncontrolled reports of benefit from America and the original trial ofFischer et al.6 did use a fixed pressure ofhyperbaric oxygen at 2 atmospheres. In addition, those who suggest that a pressure of 1.5 or 1.6 atmospheres provides a more optimal treatment are predominantly advocating monoplace therapy; the Newcastle trial2; however, used multiplace therapy at 2 atmospheres ofpressure, which yields an oxygen saturation to the patient similar to that of 1.5-1.6 atmospheres in a monoplace system.
Other criticisms have related to the methods used for assessment of the patient. Whilst it must be recognized that there is no perfect system for assessing objectively the status of patients with MS, the Kurtzke scale, the Kurtzke disability status assessment and the mobility scales used are recognized systems of assessment throughout the world and the number ofpatients examined in this way must help to obviate these criticisms.
Assessing benefit
The question then arises as to why the proponents of hyperbaric oxygenation should be so insistent upon their claims that the treatment is of benefit to their patients. There is, of course, the inevitable fact that the provision of these chambers throughout the country represents a significant investment in personal effort, time and money which it will be so hard to accept has been fruitless. But there are also significant numbers of patients who have not provided the initial capital investment and yet who feel that they have really benefited from the treatment.
The explanation for this is apparent from an evaluation of the control populations in both of the large British double-blind studies. In each case almost half the patients who received treatment felt that they had gained some benefit, but an almost identical number ofpatients receiving placebo therapy claimed the same improvement. This illustrates the vital need in assessing any treatment, but particularly treatment for a chronic relapsing and remitting disease such as MS, for a population who will act as controls. It is well recognized that patients with MS may appreciate a variation in their symptoms from month to month, day to day and even hour to hour, and unless this variation is taken into account any form of therapy can be made to appear effective in almost half the patients. It is therefore particularly important that subjective improvement in all the controlled trials reported has been noticed by a similar number of patients in both treatment and control groups. Objective,improvements assessed by the attending neurologists have been few and equally divided between treated and control populations. It is always possible with large controlled trials that there exists within the total cohort a small minority ofpatients who genuinely gain benefit from the treatment under investigation. Such benefit may be missed in a statistical analysis of the total patient groups, but ifthere are patients who have benefited in this way it must surely now be the responsibility of proponents of the therapy to identify them and to prove that a genuine benefit exists.
It is disappointing, but perhaps inevitable, that in this age ofimproving communications it is still easier to find a publisher for work which suggests a possible benefit for a conditioneven when the study is small in size or uncontrolledthan for a more significant but negative study. This factor has been borne out by the publication delay incurred by the authors' of the second major negative study of hyperbaric oxygenation in MS in the UK. However, now that negative results have been reported in two major British studies"2, three smaller controlled American studies8 -10 and a Swedish study", it must surely be concluded that hyperbaric oxygenation has no part to play in the management of the patient with MS.
